Triple-Combo Treatment of Smoldering Multiple Myeloma May Stall Disease Progression
Early treatment with a combination of anti-cancer drugs in patients with smoldering myeloma, who are at high risk of developing multiple myeloma, may avoid disease…
Myeloma
Specialty US Pharmacy, Diplomat, to Dispense Darzalex Combo to Advanced Myeloma Patients
The monoclonal antibody Darxalex (daratumumab) was recently approved by the U.S. Food and Drug Administration (FDA), in combination with either Revlimid (lenalidomide) and dexamethasone, or…
Aduro Presents Positive Results on BION-1301 for Treating Multiple Myeloma
Aduro Biotech recently presented positive preclinical data showing that its monoclonal antibody, BION-1301, may successfully inhibit multiple myeloma tumor growth, survival, and resistance to other…
2 Common Additions to Multiple Myeloma Therapy Don’t Offer Added Benefit, Study Says
The results of a new clinical trial suggest that two extension treatments that are frequently added to standard therapy care in patients with multiple…
Bluebird’s CAR T-cell Therapy Shows Promise in Advanced Multiple Myeloma Patients
Patients with advanced multiple myeloma may benefit from bluebird bio’s novel CAR T-cell therapy bb2121, according to data presented at the 28th EORTC-NCI-AACR Molecular…
Blood Purification Technique Could Offer Therapeutic Benefits for Multiple Myeloma
A technique called extracorporeal blood purification (EBP) could be used to remove certain molecules from the blood and potentially treat different conditions including multiple myeloma and kidney complications associated with it.
Extra Weight in Precancerous Stages Increases Risk of Multiple Myeloma, Study Finds
Patients in a precancerous stage of multiple myeloma would be wise to avoid gaining extra weight, according to new research that shows being overweight or obese…
Ninlaro Granted Conditional Approval by European Commission to Treat Multiple Myeloma
The European Commission has granted conditional marketing authorization to Ninlaro (ixazomib) capsules in combination with Revlimid (lenalidomide) and Decadron (dexamethasone) for multiple myeloma patients who…
Nonspecific Symptoms Including Back Pain Should Be Red Flags for Myeloma, Study Suggests
A combination of nonspecific symptoms, including back pain and weight loss, should alert physicians to the possibility of multiple myeloma. Still, the recognition of symptom patterns…
FDA OKs Darzalex as Combination Therapy for Relapsed or Refractory Myeloma Patients
The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, or Velcade (bortezomib) and dexamethasone, for multiple…
